Botulinum Toxin Injections for Sinus-Related Headache Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for headache and facial pain associated with acute recurrent or chronic sinusitis are ineffective, as they fail to address the underlying sensitization of the trigeminal nerve and persistent pain despite the absence of active sinus inflammation.
Innovation Solution
Administering a therapeutically effective amount of botulinum toxin to the nasal mucosa or subcutaneous structures overlying the sinuses, specifically targeting the dermatomes corresponding to the sinus sensory innervation, to reduce headache and facial pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for sinusitis-related headache and facial pain, then the standard of care is maintained, but the treatments are ineffective in relieving pain when active sinus inflammation is absent
Solution Approach 1:
The patent changes the therapeutic parameter from treating active inflammation (antibiotics, decongestants) to treating sensitized nerve endings (botulinum toxin injections in the trigeminal nerve distribution). This parameter shift enables effective treatment of pain persisting after sinus inflammation has resolved, addressing the contradiction between maintaining standard care and achieving effectiveness in post-inflammatory pain states.
2Reliability
If botulinum toxin is administered to treat sinusitis-related pain, then significant pain relief is achieved (80% reduction), but this represents a departure from conventional treatment protocols
Solution Approach 1:
The patent introduces botulinum toxin as an intermediary substance that blocks neurotransmitter release at sensitized nerve endings in the trigeminal distribution. This intermediary mechanism provides effective pain relief without requiring active sinus inflammation, bridging the gap between conventional treatments (which only work during active inflammation) and the need for effective post-inflammatory pain management.
3Reliability
If botulinum toxin injections are administered to the nasal mucosa or subcutaneous structures, then headache and facial pain are reduced, but the treatment requires precise targeting of dermatomes corresponding to sinus sensory innervation
Solution Approach 1:
The patent applies local quality by administering botulinum toxin specifically to subcutaneous structures overlying the sinuses and nasal mucosa in the dermatomes corresponding to sinus sensory innervation. This localized approach concentrates the therapeutic effect at the site of sensitized nerve endings while minimizing systemic effects, achieving reliable pain relief with relatively simple injection techniques targeting specific anatomical regions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides significant pain relief for patients with sinus-related headaches and facial pain, with an 80% reduction in pain severity or frequency observed in clinical trials, lasting approximately 12 weeks with repeated injections.
Implementation Method 1
Botulinum neurotoxin, a toxin isolated from a strain of Clostridium botulinum, has been used as a valuable therapeutic for the treatment of many neuromuscular diseases... The present inventors have discovered that botulinum toxin relieves the headache and facial pain associated with sinusitis.
Data Source
AI summary
The present invention provides methods for treating sinus-evoked headaches using botulinum toxin injected or applied in multiple subcutaneous locations over divisions of the trigeminal nerve in soft tissues and dermatomes overlying the corresponding effected sinuses implicated in the etiology of the pain.